Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02098616 · ClinicalTrials.gov registry record · NA
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
A NA study of Hepatitis C, sponsored by Timothy Morgan, MD.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02098616: Completed NA study of Hepatitis C, sponsored by Timothy Morgan, MD.
NCT02098616 is a NA study of Hepatitis C that has completed, run by Timothy Morgan, MD. The registered enrollment target is 25 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02098616, a NA study of Hepatitis C, has completed, sponsored by Timothy Morgan, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.
Primary Outcome
Proportion of treated subjects in each enrolled arm with sustained virologic response (SVR)12. SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Week 12
Conditions Studied
Interventions
- DRUG DCV/ASV/BMS-791325
- DRUG DCV/ASV/BMS-791325 + RBV
Study Locations (1)
California
- VA Long Beach Healthcare System - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-02 |
| Phase | NA |
What the finished NCT02098616 record still lists
NCT02098616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which DCV/ASV/BMS-791325 is the first listed.
NCT02098616 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02098616 about?
NCT02098616 is a clinical study titled "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus". The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.
What is the current status of trial NCT02098616?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2014-07. Estimated completion is 2016-02.
What conditions does trial NCT02098616 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT02098616?
The interventions under investigation include: DCV/ASV/BMS-791325 (DRUG), DCV/ASV/BMS-791325 + RBV (DRUG).
Who is sponsoring clinical trial NCT02098616?
This trial is sponsored by Timothy Morgan, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02098616 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02098616's enrollment target sits among peer trials
25 90th of 106 higher than 17 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
HCV Tappt Adherence Study
RECRUITING · NA
-
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
RECRUITING · NA
-
Buprenorphine Integration Research and Community Health
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia